Intranasal stimulation for enhanced release of ocular mucins and other tear proteins

• US 10,426,958 B2
• Filed: 12/01/2016
• Issued: 10/01/2019
• Est. Priority Date: 12/04/2015
• Status: Active Grant

• Current Assignee: Oculeve Incorporated (Abbvie Incorporated)
• Original Assignee: Oculeve Incorporated (Abbvie Incorporated)
• Inventors: Loudin, James Donald, Franke, Manfred, Ackermann, Douglas Michael
• Primary Examiner(s): Evanisko, George R
• Application Number:
  US15/367,030
• Publication Number:
  US 20170157401A1
• Time in Patent Office: 1,034 Days
• CPC Class Codes: A61B 2562/04 Arrangements of multiple sensors of the same type
• CPC Class Codes: A61B 5/053 Measuring electrical impedance or conductance of a portion of the body
• CPC Class Codes: A61B 5/0538 invasively, e.g. using a catheter
• CPC Class Codes: A61B 5/389 Electromyography [EMG]
• CPC Class Codes: A61B 5/395 Details of stimulation, e.g. nerve stimulation to elicit EMG response
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61B 5/6819 Nose
• CPC Class Codes: A61N 1/0546 Nasal electrodes
• CPC Class Codes: A61N 1/36031 using physiological parameters for adjustment
• CPC Class Codes: A61N 1/36034 specified by the stimulation parameters
• CPC Class Codes: A61N 1/36046 of the eye

Abstract

Described here are devices and methods for increasing ocular mucin and other tear protein release using intranasally delivered electrical stimulation. Generally, the devices may deliver electrical stimulation to the nasal mucosa. Intranasal stimulation may trigger degranulation of conjunctival goblet cells, which in turn releases secretory mucins into the tear fluid. The intranasal stimulation may also trigger release of lysozyme, lactoferrin, and other tear proteins into the aqueous layer of the tear film. The methods may further comprise obtaining feedback relating to the efficacy of the delivered electrical stimulation by measuring impedance or an electromyogram (EMG) signal.

Claims

1. A method for increasing ocular mucin on an ocular surface of a subject, comprising:

applying one or more active agents to the ocular surface prior to intranasally delivering an electrical stimulation to the subject, thereby increasing a density of goblet cells on the ocular surface, the one or more active agents comprising cyclosporine;

intranasally delivering the electrical stimulation to the subject after applying the one or more active agents to the ocular surface; and

stimulating release of the ocular mucin from the goblet cells,

wherein the increased density of goblet cells and the released ocular mucin from the goblet cells improves a condition of an eye of the subject.

2. The method of claim 1, wherein the electrical stimulation is intranasally delivered for at least three minutes.

3. The method of claim 2, further comprising:

measuring an impedance or an electromyogram signal from a facial muscle of the subject; and

verifying, based on the measured impedance or electromyogram signal, the intranasal delivery of the electrical stimulation for at least three minutes.

4. The method of claim 1, wherein the electrical stimulation is intranasally delivered for at least 30 seconds.

5. The method of claim 4, further comprising:

measuring an impedance or an electromyogram signal from a facial muscle of the subject; and

verifying, based on the measured impedance or electromyogram signal, the intranasal delivery of the electrical stimulation for at least 30 seconds.

6. The method of claim 1, further comprising repeating the intranasal delivery of the electrical stimulation.

7. The method of claim 1, wherein the electrical stimulation is intranasally delivered to a nasal mucosa.

8. The method of claim 1, wherein the condition of the eye is an ocular surface disease.

9. The method of claim 1, wherein the condition of the eye is dry eye.

10. The method of claim 1, wherein the condition of the eye is ocular inflammation.

11. The method of claim 10, wherein the ocular inflammation is due to Sjö

gren'"'"'s syndrome.

12. The method of claim 1, further comprising administering an additional treatment for the condition of the eye.

13. The method of claim 12, wherein the additional treatment comprises application of artificial tears to the ocular surface.

14. The method of claim 12, wherein the additional treatment comprises application of one or more second active agents to the ocular surface.

15. The method of claim 14, wherein the one or more second active agents comprises lifitegrast.

16. The method of claim 14, wherein the one or more second active agents comprises one or more antibacterial agents, one or more anti-inflammatory agents, one or more antihistamines, one or more immunomodulators, one or more immunohistomodulators, or combinations thereof.

17. The method of claim 1, wherein the intranasal delivery of the electrical stimulation comprises delivering an electrical stimulus comprising a waveform having on and off periods.

18. The method of claim 1, wherein the electrical stimulation is intranasally delivered using a stimulator, the stimulator comprising a stimulator body and a stimulator probe, wherein the stimulator probe comprises a nasal insertion prong.

19. The method of claim 18, further comprising:

positioning a portion of the nasal insertion prong in contact with a nasal mucosa.

20. The method of claim 19, wherein the portion of the nasal insertion prong in contact with the nasal mucosa is in proximity to the anterior ethmoidal nerve.

21. The method of claim 18, wherein the nasal insertion prong comprises a hydrogel electrode.

22. The method of claim 18, wherein the stimulator body is sized for holding in one hand.

23. The method of claim 18, wherein the stimulator probe comprises two nasal insertion prongs.

24. The method of claim 23, wherein the two nasal insertion prongs are biased toward each other.

25. The method of claim 24, wherein the bias of the two nasal insertion prongs holds the stimulator in the nose during the intranasal delivery of the electrical stimulation.

26. The method of claim 1, wherein the intranasal delivery of the electrical stimulation acutely increases a concentration of the ocular mucin on the ocular surface.

27. The method of claim 1, wherein the intranasal delivery of the electrical stimulation results in a sustained increase in a concentration of the ocular mucin on the ocular surface.

28. The method of claim 1, wherein the released ocular mucin repairs at least a portion of an ocular glycocalyx.

29. The method of claim 1, further comprising identifying an optimal stimulation location for intranasally delivering the electrical stimulation.

30. The method of claim 29, wherein the identifying the optimal stimulation location comprises monitoring impedance or obtaining feedback from an electromyogram (EMG) signal from a facial muscle near the nose, cheeks, or around the eyes.

31. The method of claim 30, wherein the impedance or the EMG signal is measured intranasally by a device that delivers the electrical stimulation.

32. The method of claim 30, wherein the impedance or the EMG signal is measured using an extranasal device.

33. The method of claim 32, wherein the extranasal device comprises a nose strip.

34. The method of claim 1, further comprising optimizing one or more parameters of the intranasally delivered electrical stimulation, wherein the one or more optimized parameters is selected from the group consisting of duration of stimulation, type of stimulation waveform, frequency of the stimulation waveform, amplitude of the stimulation waveform, pulse width of the stimulation waveform, and combinations thereof.

35. The method of claim 34, wherein the one or more optimized parameters is duration of stimulation.

36. The method of claim 34, wherein the one or more optimized parameters is amplitude of the stimulation waveform.